Alpha Teknova (TKNO) versus Its Peers Head-To-Head Contrast

Alpha Teknova (NASDAQ:TKNOGet Rating) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Alpha Teknova to similar businesses based on the strength of its institutional ownership, valuation, analyst recommendations, earnings, risk, dividends and profitability.

Insider and Institutional Ownership

25.5% of Alpha Teknova shares are held by institutional investors. Comparatively, 53.3% of shares of all “Diagnostic substances” companies are held by institutional investors. 10.0% of shares of all “Diagnostic substances” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Alpha Teknova and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alpha Teknova -37.59% -10.15% -8.46%
Alpha Teknova Competitors -2,287.08% -1,244.60% -26.47%

Earnings & Valuation

This table compares Alpha Teknova and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Alpha Teknova $36.89 million -$9.80 million -9.90
Alpha Teknova Competitors $409.34 million $33.17 million -89.20

Alpha Teknova’s peers have higher revenue and earnings than Alpha Teknova. Alpha Teknova is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Alpha Teknova and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpha Teknova 0 0 4 0 3.00
Alpha Teknova Competitors 252 781 1246 40 2.46

Alpha Teknova currently has a consensus price target of $27.33, suggesting a potential upside of 184.72%. As a group, “Diagnostic substances” companies have a potential upside of 94.22%. Given Alpha Teknova’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Alpha Teknova is more favorable than its peers.

Summary

Alpha Teknova beats its peers on 7 of the 12 factors compared.

About Alpha Teknova (Get Rating)

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.

Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.